LONDON (Reuters) - AstraZeneca has agreed to sell its Alderley Park research site in northern England to a public-private partnership group as it moves drug discovery to a new global centre in Cambridge. FULL ARTICLE AT Reuters.co.uk
LONDON, March 12 (Reuters) - AstraZeneca has agreed to sell its Alderley Park research site in northern England to a public-private partnership group as it moves drug discovery to a new global centre... FULL ARTICLE AT Reuters
AstraZeneca (AZN) will take a pretax impairment charge of $275M after agreeing to sell its Alderley Park R&D site in northern England to Manchester Science Parks, a public-private partnership group. AstraZeneca didn't provide financial terms of the deal ... FULL ARTICLE AT Seeking Alpha
The British pharmaceuticals group said it would take pretax impairment charges of $275 million to non-core R&D expense in the first quarter of 2014 in connection with the changes. FULL ARTICLE AT The Economic Times, India
Share this page
About this topic
AstraZeneca plc (LSE: AZN, OMX: AZN, NYSE: AZN), is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries, as 3 divisions that were spun off from ICI on 1 June 1993. The Company is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
Article At Wikipedia.org